New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries.

Belarus Eurasia Georgia Harm reduction Kazakhstan Kyrgyzstan Moldova NPS New psychoactive substances Serbia

Journal

Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624

Informations de publication

Date de publication:
30 11 2020
Historique:
received: 01 09 2020
accepted: 20 11 2020
entrez: 1 12 2020
pubmed: 2 12 2020
medline: 9 11 2021
Statut: epublish

Résumé

This study examines the use of new psychoactive substances (NPS) and the harm reduction response in six Eurasian countries: Belarus, Moldova, Serbia, Kazakhstan, Kyrgyzstan, and Georgia. The aim is to identify current patterns of NPS use and related harms in each country through recording the perspectives and lived experience of people who use drugs and people who provide harm reduction services in order to inform the harm reduction response. The study involved desk-based research and semi-structured interviews/focus groups with 124 people who use drugs and 55 health and harm reduction service providers across the six countries. People who use drugs in all countries were aware of NPS, primarily synthetic cathinones and synthetic cannabinoids. NPS users generally reflected two groups: those with no prior history of illicit drug use (typically younger people) and those who used NPS on an occasional or regular basis due to the lack of availability of their preferred drug (primarily opiates). In many cases, these respondents reported they would not use NPS if traditional opiates were available. Common factors for choosing NPS included cost and accessibility. Respondents in most countries described NPS markets that use the DarkNet and social media for communication, secretive methods of payment and hidden collection points. A recurring theme was the role of punitive drug policies in driving NPS use and related harms. Respondents in all countries agreed that current harm reduction services were important but needed to be enhanced and expanded in the context of NPS. The study identified patterns and drivers of NPS use, risk behaviours and drug-related harms. It identified gaps in the current harm reduction response, particularly the needs of non-injectors and overdose response, as well as the harmful effects of punitive drug policies. These findings may inform and improve current harm reduction services to meet the needs of people who use NPS.

Sections du résumé

BACKGROUND
This study examines the use of new psychoactive substances (NPS) and the harm reduction response in six Eurasian countries: Belarus, Moldova, Serbia, Kazakhstan, Kyrgyzstan, and Georgia. The aim is to identify current patterns of NPS use and related harms in each country through recording the perspectives and lived experience of people who use drugs and people who provide harm reduction services in order to inform the harm reduction response.
METHODOLOGY
The study involved desk-based research and semi-structured interviews/focus groups with 124 people who use drugs and 55 health and harm reduction service providers across the six countries.
RESULTS
People who use drugs in all countries were aware of NPS, primarily synthetic cathinones and synthetic cannabinoids. NPS users generally reflected two groups: those with no prior history of illicit drug use (typically younger people) and those who used NPS on an occasional or regular basis due to the lack of availability of their preferred drug (primarily opiates). In many cases, these respondents reported they would not use NPS if traditional opiates were available. Common factors for choosing NPS included cost and accessibility. Respondents in most countries described NPS markets that use the DarkNet and social media for communication, secretive methods of payment and hidden collection points. A recurring theme was the role of punitive drug policies in driving NPS use and related harms. Respondents in all countries agreed that current harm reduction services were important but needed to be enhanced and expanded in the context of NPS.
CONCLUSIONS
The study identified patterns and drivers of NPS use, risk behaviours and drug-related harms. It identified gaps in the current harm reduction response, particularly the needs of non-injectors and overdose response, as well as the harmful effects of punitive drug policies. These findings may inform and improve current harm reduction services to meet the needs of people who use NPS.

Identifiants

pubmed: 33256747
doi: 10.1186/s12954-020-00448-2
pii: 10.1186/s12954-020-00448-2
pmc: PMC7703505
doi:

Substances chimiques

Illicit Drugs 0
Psychotropic Drugs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

94

Références

Euro Surveill. 2016 May 12;21(19):
pubmed: 27195614
Subst Use Misuse. 2015;50(7):848-58
pubmed: 25775136
Int J Drug Policy. 2015 Dec;26(12):1171-6
pubmed: 26298332
Addiction. 2017 Jan;112(1):36-38
pubmed: 27546297
Int J Drug Policy. 2012 May;23(3):188-97
pubmed: 22342322
Int J Drug Policy. 2020 Mar;77:102672
pubmed: 32032867
Int J Drug Policy. 2017 Feb;40:111-116
pubmed: 27956185
Drug Test Anal. 2014 Jul-Aug;6(7-8):850-60
pubmed: 24832864
Life Sci. 2014 Feb 27;97(1):2-8
pubmed: 23911668
Harm Reduct J. 2017 Feb 10;14(1):9
pubmed: 28187774
Int J Drug Policy. 2017 Feb;40:117-122
pubmed: 27889115
Int J Drug Policy. 2017 Mar;41:1-7
pubmed: 27984762
Forensic Sci Int. 2014 Oct;243:23-9
pubmed: 24726531
Sci Total Environ. 2020 Jul 10;725:138376
pubmed: 32298891
Hum Psychopharmacol. 2013 Jul;28(4):332-40
pubmed: 23881881
Harm Reduct J. 2019 Jan 17;16(1):5
pubmed: 30654803
Lancet HIV. 2017 Aug;4(8):e357-e374
pubmed: 28515014

Auteurs

Eliza Kurcevič (E)

Eurasian Harm Reduction Association, Verkių g. 34B, office 701, 08221, Vilnius, Lithuania.

Rick Lines (R)

School of Law, Swansea University, Richard Price Building, Singleton Park, Swansea, SA2 8PP, UK. Richard.Lines@Swansea.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH